Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?

Giandomenico Roviello, Silvia Paola Corona, Raffaele Conca, Roberto Petrioli, Pietro Rosellini, Alberto Bonetta, Michele Aieta

Research output: Contribution to journalArticle

Abstract

The aim of this paper was to evaluate the activity and tolerability of oral vinorelbine in patients with advanced castration resistant prostate cancer (CRPC) who progressed after a minimum of three lines including: abiraterone acetate, docetaxel, cabazitaxel, and enzalutamide.Treatment consisted of weekly oral vinorelbine 60 mg/m. Chemotherapy was administered until disease progression or unacceptable toxicity.Twenty-six patients received vinorelbine: their median age was 74 years (range 58-84 years). Twenty-four (92.3%) patients had bone metastases. A decrease in PSA levels ≥50% was observed in 2 patients (7.7%). Among the subjects who were symptomatic at baseline, pain was reduced in 3 patients (13.6%) with a significant decrease in analgesic use. Median progression-free survival was 9 weeks (95% CI: 7 to 11) and median overall survival was 17 weeks (95% CI: 12 to 22). Treatment was well tolerated, and no grade 4 toxicities were observed.Our findings do not suggest the use of oral vinorelbine on a weekly schedule, in CRPC heavily pre-treated.

Original languageEnglish
Pages (from-to)e16249
JournalMedicine
Volume98
Issue number26
DOIs
Publication statusPublished - Jun 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this